Localization of a mutant p53 response element on the Tissue Inhibitor of Metalloproteinase-3 promoter: Mutant p53 activities are distinct from wild-type

Cancer Letters

Volumn 240, Issue 1, 2006, Pages 48-59

  Thomas, Shana ^a   Reisman, David ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Gene expression; Metalloproteinase; Oncogenic mutants; p53 tumor suppressor

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; MUTATION; REPRESSOR PROTEINS; RESPONSE ELEMENTS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745826275     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.08.027     Document Type: Article

References (48)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
2. Sharpless N.E., and DePinho R.A. p53: good cop/bad cop. Cell 110 (2002) 9-12
3. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2000) 594-604
4. Hussain S.P., and Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58 (1998) 4023-4037
5. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., et al. Gain of function mutations in p53. Nat. Genet. 4 (1993) 42-46
6. Liu G., McDonnell T.J., Montes de Oca Luna R., Kapoor M., Mims B., El-Naggar A.K., et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl Acad. Sci. USA 97 (2000) 4174-4179
7. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni. Cell 119 (2004) 847-860
8. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni. Cell 119 (2004) 861-872
9. Kim E., and Deppert W. Transcriptional activities of mutant p53: when mutations are more than a loss. J. Cell. Biochem. 93 (2004) 878-886
10. Vousden K.H., and Prives C. P53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
11. Gagnebin J., Kovar H., Kajava A.V., Estreicher A., Monnierand P., and Iggo R. Use of transcription reporters with novel p53 binding sites to target tumor cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 6 (1998) 685-690
12. Koga H., and Deppert W. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-Ser245). Oncogene 19 (2000) 4178-4183
13. Friedlander P., Haupt Y., Prives C., and Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16 (1996) 4961-4971
14. Loging T., and Reisman D. Inhibition of the putative tumor suppressor gene TIMP-3 by an oncogenic tumor derived p53 mutant. Oncogene 18 (1999) 7608-7615
15. Weisz L., Zalcentstein A., Stamolsky P., Cohen Y., Goldfinger N., Oren M., et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 64 (2004) 8318-8327
16. Scian M.J., Stagliano K.E., Deb D., Carchman E.H., Das A., Valerie K., et al. Tumor derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23 (2004) 4430-4443
17. Scian M.J., Stagliano K.E., Ellis M.A., Hassan S., Bowman M., Miles M.F., et al. Modulation of gene expression by tumor derived p53 mutants. Cancer Res. 64 (2004) 7447-7454
18. Chin K.V., Ueda K., Pastan I., and Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255 (1992) 459-462
19. Frazier M.W., He X., Wang J., Gu Z., Cleveland J.L., and Zambetti G.P. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol. 18 (1998) 3735-3743
20. Lee K., Crowe A., and Barton M. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol. Cell. Biol. 19 (1999) 1279-1288
21. Foley J., Wysolmerski J.J., Broadus A.E., and Philbrick W.M. Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53. Cancer Res. 56 (1996) 4056-4062
22. Zalcenstein A., Stamolsky P., Weisz L., Muller M., Wallach D., Goncharov D., et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor associated p53 mutants. Oncogene 22 (2003) 5667-5676
23. Will K., Warnecke G., Wiesmuller L., and Deppert W. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc. Natl Acad. Sci. USA 95 (1998) 13681-13686
24. Gualberto A., Aldape K., Kozakiewics K., and Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl Acad. Sci. USA 95 (1998) 5166-5171
25. DiComo C.J., Gaiddon C., and Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19 (1999) 1438-1449
26. Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275 (2000) 29503-29512
27. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21 (2001) 1874-1887
28. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277 (2002) 18817-18826
29. Mohammed F.F., Smookler D.S., Taylor S.E., Fingleton B., Kassiri Z., Sanchez O.H., et al. Abnormal TNF activity in Timp-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. 36 (2004) 969-977
30. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477 (2000) 267-283
31. Andreu T., Beckers T., Thoenes E., Hilgard P., and von Melchner H. Gene trapping identifies inhibitors of oncogenic transformation. The TIMP3 and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J. Biol. Chem. 273 (1998) 13848-13854
32. Bian J., Jacobs C., Wang Y., and Sun Y. Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. Carcinogenesis 17 (1996) 2559-2562
33. Pennie W.D., Hegamyer G.A., Young M.R., and Colburn N.H. Specific methylation events contribute to the transcriptional repression of the mouse tissue inhibitor of metalloproteinases-3 gene in neoplastic cells. Cell Growth. Differ. 10 (1999) 279-286
34. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., and Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61 (2001) 249-255
35. Dulaimi E., Ibanez de Caceres I., Uzzo R.G., Al-Saleem T., Greenberg R.E., Polascik T.J., et al. Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. 10 (2004) 3972-3979
36. Sun Y., Hegamyer G., Kim H., Sithanandam K., Li H., Watts R., et al. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J. Biol. Chem. 270 (1995) 19312-19319
37. El-Diery W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8 (1998) 345-357
38. Anand-Apte B., Bao L., Smith R., Iwata K., Olsen B.R., Zetter B., et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem. Cell Biol. 74 (1996) 853-862
39. Matrisian L.M. Cancer biology: extracellular proteinases in malignancy. Curr. Biol. 9 (1999) 776-778
40. Matrisian L.M., Sledge G.W., and Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63 (2003) 6105-6109
41. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370 (1994) 61-65
42. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85 (1996) 683-693
43. Blobel C.P. Metalloproteinase-disintigrins: links to cell adhesion and cleavage of TNFα and notch. Cell 90 (1997) 589-592
44. Ueno H., Nakamura H., Inoue M., Imai K., Noguchi M., Sato H., et al. Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57 (1997) 2055-2060
45. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
46. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14 (2000) 163-176
47. Freedman D.A., and Levine A.J. Regulation of the p53 protein by the MDM2 oncoprotein. Cancer Res. 59 (1999) 1-7
48. Kinzler K.W., and Vogelstein B. Colorectal tumors. In: Kinzler K.W., and Vogelstein B. (Eds). The Genetic Basis of Human Cancers (1998), McGraw-Hill, New York 565-587